Tislelizumab Plus TP as Neoadjuvant Therapy for Local Advanced Cervical Carcinoma
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trail is to investigate the efficacy and safety of PD-1 antibody
Tislelizumab plus TP regimen (taxane combined with platinum) as neoadjuvant therapy for
patients diagnosed as local advanced cervical carcinoma (FIGO staging IB2-IIB).